Cagan Gurer is the Vice President of Discovery at TScan Therapeutics.  Prior to joining TScan, Cagan was the Executive Director of Cell Therapy at Kite where he led the TCR discovery efforts and solid tumor T-cell therapy strategy. Before joining Kite, Cagan, was the Senior Director of Immune Technology Development at Regeneron Pharmaceuticals, Inc. where he spearheaded the improvements to the VelocImmune® mouse platform that is responsible for producing fully human monoclonal and bispecific antibodies as well as establishing the VelociT™ mouse pipeline that generates human therapeutic T-cell receptors.  Cagan received his Ph.D. in microbiology from Columbia University and completed his postdoctoral training in immunology with Drs. Christian Münz and Ralph Steinman at the Rockefeller University.